The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy
DR Principe, PW Underwood, M Korc… - Frontiers in …, 2021 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …
Regulation and function of autophagy in pancreatic cancer
Oncogenic KRAS mutation-driven pancreatic ductal adenocarcinoma is currently the fourth-
leading cause of cancer-related deaths in the United States. Macroautophagy (hereafter …
leading cause of cancer-related deaths in the United States. Macroautophagy (hereafter …
Combination of antimalarial and CNS drugs with antineoplastic agents in MCF-7 breast and HT-29 colon cancer cells: Biosafety evaluation and mechanism of action
Drug combination and drug repurposing are two strategies that allow to find novel
oncological therapies, in a faster and more economical process. In our previous studies, we …
oncological therapies, in a faster and more economical process. In our previous studies, we …
Laminarin attenuates ROS-mediated cell migration and invasiveness through mitochondrial dysfunction in pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) is a notoriously aggressive type of cancer with a
high metastasis rate. It is conventionally treated by surgical resection and neoadjuvant …
high metastasis rate. It is conventionally treated by surgical resection and neoadjuvant …
CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target
L Li, L Zhong, C Tang, L Gan, T Mo, J Na, J He… - Clinical and …, 2022 - Springer
Cancer is one of the diseases with the highest morbidity and mortality rates worldwide, and
its therapeutic options are inadequate. The endothelial glycoprotein, also known as CD105 …
its therapeutic options are inadequate. The endothelial glycoprotein, also known as CD105 …
Antitumor effects of cannabinoids in human pancreatic ductal adenocarcinoma cell line (Capan-2)-Derived xenograft mouse model
S Sakarin, N Meesiripan, S Sangrajrang… - Frontiers in Veterinary …, 2022 - frontiersin.org
Background Pancreatic cancer is considered a rare type of cancer, but the mortality rate is
high. Cannabinoids extracted from the cannabis plant have been interested as an …
high. Cannabinoids extracted from the cannabis plant have been interested as an …
Evening primrose seed extract rich in polyphenols modulates the invasiveness of colon cancer cells by regulating the TYMS expression
WM Ciszewski, J Włodarczyk… - Food & Function, 2022 - pubs.rsc.org
Natural polyphenols are plant metabolites exhibiting a broad range of biological activities.
Among them, anticancer properties seem to be very desirable. This study examined the …
Among them, anticancer properties seem to be very desirable. This study examined the …
Cancer stem cell marker endoglin (CD105) induces epithelial mesenchymal transition (EMT) but not metastasis in clear cell renal cell carcinoma
J Hu, W Guan, L Yan, Z Ye, L Wu… - Stem Cells International, 2019 - Wiley Online Library
Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney
cancer. We previously reported that CD105 (+) subpopulation in human ccRCC tumors …
cancer. We previously reported that CD105 (+) subpopulation in human ccRCC tumors …
Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy
Y Yu, F Yang, W Zhang, Y Guo, L Ye, X Yao - Cell & Bioscience, 2021 - Springer
Abstract Background Mesenchymal stem cells (MSCs) have been proved to drive castration
resistant prostate cancer (CRPC). In this study, we aim to investigate the contribution of …
resistant prostate cancer (CRPC). In this study, we aim to investigate the contribution of …
ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway
J Gu, K Zhong, L Wang, H Ni, Y Zhao, X Wang… - Frontiers in …, 2022 - frontiersin.org
Introduction Chemoresistance is a major barrier in the treatment of colorectal cancer (CRC)
and many other cancers. ENO1 has been associated with various biological characteristics …
and many other cancers. ENO1 has been associated with various biological characteristics …